Francisco Sapunar
- Oncology top 2%
- HER2/EGFR in Cancer Research 7
- Cancer Treatment and Pharmacology 3
- Cancer Research top 5%
- Breast Cancer Treatment Studies 9
- Cancer Genomics and Diagnostics 3
-
- Advanced Breast Cancer Therapies 13
- Renal cell carcinoma treatment 4
- Genetics top 5%
- Estrogen and related hormone effects 9
- Hematology top 5%
- Multiple Myeloma Research and Treatments 3
- Journals
- Journal of Clinical Oncology (7 papers)Cancer Research (2 papers)The Lancet Oncology (1 paper)
- Partner nations
- United KingdomUnited StatesGermany
In The Last Decade
Francisco Sapunar
32 papers receiving 1.7k citations
Hit Papers
Peers
Comparison fields: 5 of 83
- Oncology 1.1k
- Cancer Research 522
- Pulmonary and Respiratory Medicine 846
- Genetics 585
- Hematology 171
Countries citing papers authored by Francisco Sapunar
This map shows the geographic impact of Francisco Sapunar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francisco Sapunar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francisco Sapunar more than expected).
Fields of papers citing papers by Francisco Sapunar
This network shows the impact of papers produced by Francisco Sapunar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francisco Sapunar. The network helps show where Francisco Sapunar may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Francisco Sapunar, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 3 | |
| 2 | 2023 | 2 | |
| 3 | 2022 | 12 | |
| 4 | 2022 | 7 | |
| 5 | 2022 | 3 | |
| 6 | 2016 | 19 | |
| 7 | 2012 | 67 | |
| 8 | 2011 | 27 | |
| 9 | Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancerbreakdown → | 2010 | 453 |
| 10 | 2009 | 60 | |
| 11 | 2008 | 162 | |
| 12 | 2008 | 36 | |
| 13 | 2002 | 20 | |
| 14 | 2001 | 8 | |
| 15 | 2001 | 89 | |
| 16 | 2000 | 30 | |
| 17 | 2000 | 3 | |
| 18 | 2000 | 274 | |
| 19 | 1997 | 49 | |
| 20 | [Allogenic bone marrow transplantation in the treatment of malignant hematologic disease]. | 1995 | 2 |
About Francisco Sapunar
Francisco Sapunar is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine, having authored 33 papers that have together received 1.7k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (13 papers), Estrogen and related hormone effects (9 papers), Breast Cancer Treatment Studies (9 papers), HER2/EGFR in Cancer Research (7 papers), Renal cell carcinoma treatment (4 papers), Multiple Myeloma Research and Treatments (3 papers), Cancer Treatment and Pharmacology (3 papers) and Cancer Genomics and Diagnostics (3 papers). The work is most often cited by research in Oncology (1.1k citations), Cancer Research (522 citations) and Pulmonary and Respiratory Medicine (846 citations). Francisco Sapunar has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include Aman U. Buzdar, Ivana Šestak, Jack Cuzick, Roger A’Hern, L Pyle, Ian Mak, Martin Gore, Tim Eisen, Guy Jérusalem and Sally Garnett. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.